-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225

Benzinga·11/02/2026 15:40:03
Truist Securities analyst Danielle Brill downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Buy to Hold and lowers the price target from $315 to $225.